Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2018, Article ID 9049252, 8 pages
https://doi.org/10.1155/2018/9049252
Review Article

Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity

1Laboratory of Molecular Biology & Pathology, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China
2Department of Infectious Diseases, Xi’an Central Hospital, Xi’an, Shaanxi 710000, China

Correspondence should be addressed to Xiaoping Wang; moc.nuyila@dhppxw

Received 3 December 2017; Revised 25 January 2018; Accepted 18 March 2018; Published 1 April 2018

Academic Editor: Maikel P. Peppelenbosch

Copyright © 2018 Xiaoping Wang and Qiaoxia Wang. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. G. Chen and S. W. Zhang, “Liver cancer epidemic in China: past, present and future,” Seminars in Cancer Biology, vol. 21, no. 1, pp. 59–69, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Obed, A. Bashir, and A. Jarrad, “Rapid virological response after early treatment with a combined therapy of ledipasvir and sofosbuvir in HCV genotype 4 after living donor liver transplantation in a HCC downstaged patient: Case report and review of the literature,” American Journal of Case Reports, vol. 17, pp. 672–675, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Bruix, G. J. Gores, and V. Mazzaferro, “Hepatocellular carcinoma: clinical frontiers and perspectives,” Gut, vol. 63, no. 5, pp. 844–855, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Wong and C. Frenette, “Updates in the management of hepatocellular carcinoma,” Journal of Gastroenterology and Hepatology, vol. 7, no. 1, pp. 16–24, 2011. View at Google Scholar · View at Scopus
  5. G. J. Mizejewski, “Does alpha-fetoprotein contribute to the mortality and morbidity of human hepatocellular carcinoma? A commentary,” Journal of Hepatocellular Carcinoma, vol. Volume 3, pp. 37–40, 2016. View at Publisher · View at Google Scholar
  6. F. Gao, H. K. Zhu, and Y. B. Zhu, “Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern,” vol. 15, pp. 371–377, 2016.
  7. M.-A. Buendia and C. Neuveut, “Hepatocellular carcinoma,” Cold Spring Harbor Perspectives in Medicine, vol. 5, no. 2, Article ID a021444, 2015. View at Publisher · View at Google Scholar
  8. H. Toyoda, T. Kumada, T. Tada et al., “Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL,” Cancer Science, vol. 102, no. 5, pp. 1025–1031, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Li, T. Gao, S. Gu, J. Zhi, J. Yang, and G. Li, “An electrochemical biosensor for the assay of alpha-fetoprotein-L3 with practical applications,” Biosensors and Bioelectronics, vol. 87, pp. 352–357, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. J. Yoon, K. Han, and D. Y. Kim, “Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection,” Scandinavian Journal of Gastroenterology, vol. 44, no. 7, pp. 861–866, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Stefaniuk, J. Cianciara, and A. Wiercinska-Drapalo, “Present and future possibilities for early diagnosis of hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 16, no. 4, pp. 418–424, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. Z. Zhang, Y. Zhang, Y. Wang, L. Xu, and W. Xu, “Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma,” OncoTargets and Therapy, vol. 9, pp. 123–129, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Dai, X. Chen, X. Liu et al., “Diagnostic value of the combination of golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma: A meta-analysis,” PLoS ONE, vol. 10, no. 10, Article ID e0140067, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Zhu, Y. Lu, W. Li et al., “Hepatitis B virus X protein driven alpha fetoprotein expression to promote malignant behaviors of normal liver cells and hepatoma cells,” Journal of Cancer, vol. 7, no. 8, pp. 935–946, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Meng, B. Bai, and Z. Bai, “The immunosuppression role of alpha-fetoprotein in human hepatocellular carcinoma,” Discovery Medicine, vol. 21, no. 118, pp. 489–494, 2016. View at Google Scholar
  16. W. Meng, X. Li, Z. Bai et al., “Silencing alpha-fetoprotein inhibits VEGF and MMP-2/9 production in human hepatocellular carcinoma cell,” PLoS ONE, vol. 9, no. 2, Article ID e90660, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Li, H. Li, C. Li et al., “Alpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cells,” International Journal of Cancer, vol. 124, no. 12, pp. 2845–2854, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Song, C. Song, and Y. Chen, “Polysaccharide-induced apoptosis in H22 cells through G2/M arrest and BCL2/BAX caspase-activated Fas pathway,” Cellular and Molecular Biolology (Noisy-le-grand), vol. 61, no. 7, pp. 88–95, 2015. View at Google Scholar
  19. N. Schmidt, C. Neumann-Haefelin, and R. Thimme, “Cellular immune responses to hepatocellular carcinoma: Lessons for immunotherapy,” Digestive Diseases, vol. 30, no. 5, pp. 483–491, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. A. D. Pardee, J. Shi, and L. H. Butterfield, “Tumor-derived α-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells,” The Journal of Immunology, vol. 193, no. 11, pp. 5723–5732, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Trompezinski, C. Migdal, M. Tailhardat et al., “Characterization of early events involved in human dendritic cell maturation induced by sensitizers: Cross talk between MAPK signalling pathways,” Toxicology and Applied Pharmacology, vol. 230, no. 3, pp. 397–406, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Vogt, E. Sievers, V. Lukacs-Kornek et al., “Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo,” Liver International, vol. 34, no. 3, pp. 447–461, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Yamamoto, T. Tatsumi, T. Miyagi et al., “α-Fetoprotein impairs activation of natural killer cells by inhibiting the function of dendritic cells,” Clinical & Experimental Immunology, vol. 165, no. 2, pp. 211–219, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Guerra, Y. X. Tan, N. T. Joncker et al., “NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous Malignancy,” Immunity, vol. 28, no. 4, pp. 571–580, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Liu, Y.-R. Wang, G.-H. Ding et al., “JAK2 inhibitor combined with DC-activated AFP-specific T-cells enhances antitumor function in a Fas/FasL signal-independent pathway,” OncoTargets and Therapy, vol. 9, pp. 4425–4433, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. M.-S. Li, P.-F. Li, Q. Chen, G.-G. Du, and G. Li, “Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells,” World Journal of Gastroenterology, vol. 10, no. 6, pp. 819–824, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Li, H. Li, C. Li et al., “Alpha-fetoprotein: a new member of intracellular signal molecules in regulation of the PI3K/AKT signaling in human hepatoma cell lines,” International Journal of Cancer, vol. 128, no. 3, pp. 524–532, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Zhu, J. Guo, H. Xia et al., “Alpha-fetoprotein activates AKT/mTOR signaling to promote CXCR4 expression and migration of hepatoma cells,” Oncoscience, vol. 2, no. 1, pp. 59–70, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Lu, M. Zhu, W. Li et al., “Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells,” Journal of Cellular and Molecular Medicine, vol. 20, no. 3, pp. 549–558, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Yamaguchi, H. Yano, A. Iemura, S. Ogasawara, M. Haramaki, and M. Kojiro, “Expression of vascular endothelial growth factor in human hepatocellular carcinoma,” Hepatology, vol. 28, no. 1, pp. 68–77, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Li, X. Liu, S. Zhou, P. Li, and G. Li, “Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes,” BMC Cancer, vol. 5, article no. 96, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Zhang, T. He, H. Cui, Y. Wang, C. Huang, and F. Han, “Effects of AFP gene silencing on apoptosis and proliferation of a hepatocellular carcinoma cell line.,” Discovery Medicine, vol. 14, no. 75, pp. 115–124, 2012. View at Google Scholar · View at Scopus
  33. K.-J. Chen, L. Zhou, H.-Y. Xie, T.-E. Ahmed, X.-W. Feng, and S.-S. Zheng, “Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection,” Medical Oncology, vol. 29, no. 3, pp. 1817–1826, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. S. M. Bray, L. Vujanovic, and L. H. Butterfield, “Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients,” Clinical and Developmental Immunology, vol. 2011, Article ID 249281, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. Q. Gao, S.-J. Qiu, J. Fan et al., “Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection,” Journal of Clinical Oncology, vol. 25, no. 18, pp. 2586–2593, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Li, S.-S. Wang, H. Liu et al., “Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 17, no. 41, pp. 4563–4571, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. M.-S. Li, P.-F. Li, S.-P. He, G.-G. Du, and G. Li, “The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line,” World Journal of Gastroenterology, vol. 8, no. 3, pp. 469–475, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. I. Mellman, G. Coukos, and G. Dranoff, “Cancer immunotherapy comes of age,” Nature, vol. 480, no. 7378, pp. 480–489, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. L. H. Butterfield, A. Koh, W. Meng et al., “Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein,” Cancer research, vol. 59, no. 13, pp. 3134–3142, 1999. View at Google Scholar
  40. W. S. Meng, L. H. Butterfield, A. Ribas et al., “Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human α-fetoprotein,” Molecular Immunology, vol. 37, no. 16, pp. 943–950, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. L. H. Butterfield, W. S. Meng, A. Koh et al., “T Cell Responses to HLA-A*0201-Restricted Peptides Derived from Human Fetoprotein,” The Journal of Immunology, vol. 166, no. 8, pp. 5300–5308, 2001. View at Publisher · View at Google Scholar
  42. K. Hiroishi, J. Eguchi, T. Baba et al., “Strong CD8+ T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma,” Journal of Gastroenterology, vol. 45, no. 4, pp. 451–458, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. J.-H. Lee, Y. Lee, M. Lee et al., “A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma,” British Journal of Cancer, vol. 113, no. 12, pp. 1666–1676, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. J.-Y. Yang, X. Li, L. Gao, Z.-H. Teng, and W.-C. Liu, “Co-transfection of dendritic cells with AFP and IL-2 genes enhances the induction of tumor antigen-specific antitumor immunity,” Experimental and Therapeutic Medicine, vol. 4, no. 4, pp. 655–660, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. J.-Y. Yang, D.-Y. Cao, Y. Xue, Z.-C. Yu, and W.-C. Liu, “Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells,” Human Immunology, vol. 71, no. 3, pp. 255–262, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. L. H. Butterfield, “Recent advances in immunotherapy for hepatocellular cancer,” Swiss Medical Weekly, vol. 137, no. 5-6, pp. 83–90, 2007. View at Google Scholar · View at Scopus
  47. Y. Liu, S. Daley, V. N. Evdokimova, D. D. Zdobinski, D. M. Potter, and L. H. Butterfield, “Hierarchy of α fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer,” The Journal of Immunology, vol. 177, no. 1, pp. 712–721, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. A. D. Pardee, H. Yano, A. M. Weinstein et al., “Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma,” Journal for ImmunoTherapy of Cancer, vol. 3, no. 1, article no. 32, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. Z. Li, X. P. Wang, H. P. Lin et al., “Anti-tumor immunity elicited by cross-linking vaccine heat shock protein 72 and alpha-fetoprotein epitope peptide,” Neoplasma, vol. 62, no. 5, pp. 713–721, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. X.-P. Wang, H.-P. Lin, Q.-X. Wang, and Y. Gu, “Specific antitumor immunity induced by cross-linking complex heat shock protein 72 and alpha-fetoprotein,” Cancer Biotherapy and Radiopharmaceuticals, vol. 27, no. 3, pp. 189–197, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Wang, F. Feng, X.-P. Wang et al., “Dendritic cells pulsed with Hsp70 and HBxAg induce specific antitumor immune responses in hepatitis B virus-associated hepatocellular carcinoma,” Molecular Medicine Reports, vol. 13, no. 2, pp. 1077–1082, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. D. S. Wheeler, K. E. Dunsmore, A. G. Denenberg, L. Muething, S. E. Poynter, and H. R. Wong, “Biological activity of truncated C-terminus human heat shock protein 72,” Immunology Letters, vol. 135, no. 1-2, pp. 173–179, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Shevtsov and G. Multhoff, “Heat shock protein-Peptide and HSP-based immunotherapies for the treatment of cancer,” Frontiers in Immunology, vol. 7, article no. 171, 2016. View at Publisher · View at Google Scholar · View at Scopus
  54. T.-M. Hung, R.-H. Hu, C.-M. Ho et al., “Downregulation of alpha-fetoprotein expression by LHX4: A critical role in hepatocarcinogenesis,” Carcinogenesis, vol. 32, no. 12, Article ID bgr219, pp. 1815–1823, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Tang, X.-Y. Tang, M. Liu, and X. Li, “Targeting alpha-fetoprotein represses the proliferation of hepatoma cells via regulation of the cell cycle,” Clinica Chimica Acta, vol. 394, no. 1-2, pp. 81–88, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. S.-H. Ma, G. G. Chen, J. Yip, and P. B. S. Lai, “Therapeutic effect of α-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice,” Gene Therapy, vol. 17, no. 7, pp. 905–912, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Saeki, K. Nakao, Y. Nagayama et al., “Diverse efficacy of vaccination therapy using the α-fetoprotein gene against mouse hepatocellular carcinoma,” International Journal of Molecular Medicine, 2004. View at Publisher · View at Google Scholar
  58. C. F. Grimm, D. Ortmann, L. Mohr et al., “Mouse α-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression mice,” Gastroenterology, vol. 119, no. 4, pp. 1104–1112, 2000. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Hanke, M. Serwe, F. Dombrowski, T. Sauerbruch, and W. H. Caselmann, “DNA vaccination with AFP-encoding plasmid DNA prevents growth of subcutaneous AFP-expressing tumors and does not interfere with liver regeneration in mice,” Cancer Gene Therapy, vol. 9, no. 4, pp. 346–355, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. W. S. Meng, L. H. Butterfield, A. Ribas et al., “α-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination,” Cancer Research, vol. 61, no. 24, pp. 8782–8786, 2001. View at Google Scholar · View at Scopus
  61. F. Ghasemi, S. Rostami, M. Ghayour-Mobarhan, and Z. Meshkat, “Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection,” Iranian Journal of Basic Medical Sciences, vol. 19, no. 7, pp. 692–704, 2016. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Hirayama and Y. Nishimura, “The present status and future prospects of peptide-based cancer vaccines,” International Immunology, vol. 28, no. 7, pp. 319–328, 2016. View at Publisher · View at Google Scholar · View at Scopus
  63. X. Wang, Y. Zhou, X. Ying, L. Guo, Y. Zhao, and Y. Fang, “Interaction between heat shock protein 72 and α-fetoprotein in human hepatocellular carcinomas,” Clinica Chimica Acta, vol. 379, no. 1-2, pp. 158–162, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. X. Wang, Q. Wang, H. Lin, S. Li, L. Sun, and Y. Yang, “HSP72 and gp96 in gastroenterological cancers,” Clinica Chimica Acta, vol. 417, pp. 73–79, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. X.-P. Wang, G.-Z. Liu, A.-L. Song, H.-Y. Li, and Y. Liu, “Antitumor immunity induced by DNA vaccine encoding alpha-fetoprotein/heat shock protein 70,” World Journal of Gastroenterology, vol. 10, no. 21, pp. 3197–3200, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. Y.-H. Lan, Y.-G. Li, Z.-W. Liang et al., “A DNA vaccine against chimeric AFP enhanced by HSP70 suppresses growth of hepatocellular carcinoma,” Cancer Immunology, Immunotherapy, vol. 56, no. 7, pp. 1009–1016, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. X.-P. Wang, Q.-X. Wang, H.-P. Lin, Y.-L. Wang, and Y. Yang, “Glycoprotein 96 and α-fetoprotein cross-linking complexes elicited specific antitumor immunity,” Cancer Biotherapy and Radiopharmaceuticals, vol. 28, no. 5, pp. 406–414, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. X.-P. Wang, Q.-X. Wang, H.-P. Lin, B. Xu, Q. Zhao, and K. Chen, “Recombinant heat shock protein 70 functional peptide and alpha-fetoprotein epitope peptide vaccine elicits specific antitumor immunity,” Oncotarget , vol. 7, no. 44, pp. 71274–71284, 2016. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. Nakamoto, E. Mizukoshi, M. Kitahara et al., “Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization,” Clinical & Experimental Immunology, vol. 163, no. 2, pp. 165–177, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. F. Tada, M. Abe, M. Hirooka et al., “Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma,” International Journal of Oncology, vol. 41, no. 5, pp. 1601–1609, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. L. H. Butterfield, A. Ribas, W. S. Meng et al., “Tcell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer,” Clinical Cancer Research, vol. 9, no. 16, part 1, pp. 5902–5908, 2003. View at Google Scholar · View at Scopus
  72. L. H. Butterfield, A. Ribas, V. B. Dissette et al., “A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four α-fetoprotein peptides,” Clinical Cancer Research, vol. 12, no. 9, pp. 2817–2825, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. Wang, X. Yang, Y. Yu et al., “Immunotherapy of patient with hepatocellular carcinoma using cytotoxic T lymphocytes,” Journal of Cancer, vol. 9, no. 2, pp. 275–287, 2018. View at Publisher · View at Google Scholar
  74. M. R. Hollingdale and M. Sedegah, “Development of whole sporozoite malaria vaccines,” Expert Review of Vaccines, vol. 16, no. 1, pp. 45–54, 2017. View at Publisher · View at Google Scholar · View at Scopus
  75. F. Cabillic, O. Toutirais, V. Lavoué et al., “Aminobisphosphonate-pretreated dendritic cells trigger successful Vγ9Vδ2 T cell amplification for immunotherapy in advanced cancer patients,” Cancer Immunology, Immunotherapy, vol. 59, no. 11, pp. 1611–1619, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Ding, Y. Wang, J. Chi et al., “Is adjuvant cellular immunotherapy essential after TACE-predominant minimally-invasive treatment for hepatocellular carcinoma? A systematic meta-analysis of studies including 1774 patients,” PLoS ONE, vol. 11, no. 12, Article ID e0168798, 2016. View at Publisher · View at Google Scholar · View at Scopus
  77. A. B. El-Khoueiry, B. Sangro, T. Yau et al., “Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial,” The Lancet, vol. 389, no. 10088, pp. 2492–2502, 2017. View at Publisher · View at Google Scholar · View at Scopus